GSK schedules 2026 annual general meeting

GSK plc has released the Notice of Annual General Meeting 2026 on its website and will send it to shareholders.

Accepted by SEC EDGAR 03/25/2026 - 09:23 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

GSK plc has released the Notice of Annual General Meeting 2026 on its website and will send it to shareholders. The AGM is scheduled for 6 May 2026 at 2:30pm at the London Marriott Hotel Grosvenor Square and will also be broadcast live for shareholders to join electronically. Related documents, including the 2026 AGM Notice, Proxy Form, and marked-up Articles of Association showing proposed changes, will be submitted to the UK Financial Conduct Authority for inspection via its National Storage Mechanism.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will GSK (GSK) hold its 2026 Annual General Meeting?

GSK will hold its 2026 Annual General Meeting on Wednesday 6 May 2026 at 2:30pm. The meeting will take place at the London Marriott Hotel Grosvenor Square in London and will also be broadcast live for shareholders to join electronically.

Where can GSK (GSK) shareholders find the 2026 AGM Notice?

The 2026 AGM Notice is available on GSK’s website at www.gsk.com/en-gb/investors/shareholder-information/annual-general-meeting/. It will also be distributed to shareholders and submitted to the FCA’s National Storage Mechanism for public inspection in due course.

Can GSK (GSK) shareholders attend the 2026 AGM electronically?

Yes, shareholders can join the 2026 AGM electronically via a live broadcast. Full instructions on how to join either in person at the London Marriott Hotel Grosvenor Square or electronically are set out in the 2026 AGM Notice and AGM Guide.

What documents for GSK (GSK) 2026 AGM are being submitted to the FCA?

GSK will submit three key documents to the UK Financial Conduct Authority: the 2026 AGM Notice, the Proxy Form for the AGM, and the Company’s Articles of Association marked up to show proposed changes, for inspection via the National Storage Mechanism.

What does GSK (GSK) say about forward-looking statements in this announcement?

GSK cautions that any forward-looking statements or projections in the announcement are subject to risks and uncertainties. Actual results may differ materially from projections, and key risk factors are described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2025.

What type of company is GSK (GSK) according to this filing?

GSK describes itself as a global biopharma company whose purpose is to unite science, technology, and talent to get ahead of disease together. Additional information about the business and purpose is available on its main website at gsk.com.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 25 March 2026, London UK

GSK plc Publication of Notice of Annual General Meeting 2026

The Company has today published on its website (www.gsk.com/en-gb/investors/shareholder-information/annual-general-meeting/) the Notice of Annual General Meeting ('AGM') 2026 (the '2026 AGM Notice'), which will be distributed to shareholders shortly.

The Company's AGM will be held on Wednesday 6 May 2026 at 2.30pm at the London Marriott Hotel Grosvenor Square, Grosvenor Square, London, W1K 6JP and will also be broadcast live for shareholders to join electronically. Full details of how to join the meeting either in person or electronically are contained in the 2026 AGM Notice and AGM Guide.

In compliance with Listing Rule 6.4.1R of the UK Financial Conduct Authority's ('FCA') Listing Rules, the following documents will be submitted to the FCA and will, in due course, be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism:

●   2026 AGM Notice

●   Proxy Form for the AGM

●   The Company's Articles of Association marked up to show proposed changes

V A Whyte

Company Secretary

25 March 2026 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2025.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: March 25, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc